MRK - Merck & Co., Inc.
| Previous Close | 77.42 |
| Open | 77.92 |
| Bid | 0.00 x 900 |
| Ask | 0.00 x 800 |
| Day's Range | 76.54 - 78.31 |
| 52 Week Range | 52.83 - 80.19 |
| Volume | 13,232,513 |
| Avg. Volume | 11,550,807 |
| Market Cap | 200.515B |
| Beta (3Y Monthly) | 0.61 |
| PE Ratio (TTM) | 62.44 |
| EPS (TTM) | 1.24 |
| Earnings Date | Jan 31, 2019 - Feb 4, 2019 |
| Forward Dividend & Yield | 2.20 (2.87%) |
| Ex-Dividend Date | 2018-12-14 |
| 1y Target Est | 80.07 |
- Reuters•6 hours ago
McDonald's to curb antibiotic use in its beef supply
McDonald's Corp said on Tuesday it plans to reduce the use of antibiotics in its global beef supply, fueling projections that other restaurants will follow suit. The move by the world's biggest fast-food chain addresses concerns that the overuse of antibiotics vital to fighting human infections in farm animals may diminish the drugs' effectiveness in people. McDonald's becomes the biggest beef buyer to tackle the issue in cattle, potentially creating a new standard for livestock producers and threatening sales by drug companies such as Merck & Co and Elanco Animal Health.
- InvestorPlace•14 hours ago
Moderna Stock Ushers In the Next Wave of Biotech
Moderna (NASDAQ:MRNA) went public on Dec. 7, raising $604 million on a market cap of $7.5 billion. The IPO met the goal, but a bad day on Wall Street sent the shares plummeting. It’s because Moderna represents the next wave in drug discovery. Like Regeneron Pharmaceuticals (NASDAQ:REGN), Moderna is less a bet on particular drugs than on a method for finding them.
- Benzinga•12 hours ago
Gabelli Names Clovis As Top Pick, Calls The Biotech A Likely Takeout Candidate
Clovis Oncology Inc (NASDAQ: CLVS ) has emerged as a strong takeover candidate following GlaxoSmithKline plc (NYSE: GSK )'s proposed acquisition of TESARO Inc (NASDAQ: TSRO ), according to Gabelli Research. ...
- Benzinga•16 hours ago
The Daily Biotech Pulse: Management Change At Merck, Jazz Buyback, Arrowhead Earnings
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peak (Biotech stocks hitting 52-week highs on Dec. 10) Homology Medicines Inc (NASDAQ: FIXX ) OvaScience Inc ...
Zacks•yesterdayMerck (MRK) Outpaces Stock Market Gains: What You Should Know
In the latest trading session, Merck (MRK) closed at $77.42, marking a +0.91% move from the previous day.
- Business Wire•yesterday
Merck’s President of Global Human Health Adam H. Schechter to Leave Merck Frank Clyburn Named Chief Commercial Officer and Michael Nally Named Chief Marketing Officer
Merck (MRK), known as MSD outside the United States and Canada, today announced that Adam H. Schechter, president of Global Human Health (GHH), is stepping down from his current position as of Dec. 31, 2018, and will be shifting to an advisory capacity to the CEO. The company is taking the opportunity to reshape its commercial organization and is creating two new Executive Committee roles. Frank Clyburn has been promoted to Chief Commercial Officer and Michael Nally has been promoted to Chief Marketing Officer.
- InvestorPlace•2 days ago
PFE Stock Has Broken Its Slump and Could Challenge Former Highs
Pfizer (NYSE:PFE) may find itself doing something it has not done in years—break records. The New York-based pharmaceutical giant found itself stuck as PFE stock spent years mired in a trading range. Now it looks poised to reach and surpass the highs that have eluded Pfizer for almost two decades.
- Zacks•yesterday
Roche's Tecentriq Gets FDA Approval for First-Line NSCLC
Roche's (RHHBY) Tecentriq in combination with Avastin obtains FDA nod for the initial treatment of NSCLC.
- Insider Monkey•2 days ago
Here is What Hedge Funds Are Thinking About Merck & Co., Inc. (MRK)
Amid an overall market correction, many stocks that smart money investors were collectively bullish on tanked during the fourth quarter. Among them, Amazon and Netflix ranked among the top 30 picks and both lost around 20%. Facebook, which was the second most popular stock, lost 14% amid uncertainty regarding the interest rates and tech valuations. […]
Bloomberg•4 days agoNew Biotech IPO Dropped a Unicorn-Sized Value on Its First Day
The $1.4 billion Moderna lost in value is greater than the market value of more than half the companies in the Nasdaq Biotechnology Index. The company boasts partnerships with sector juggernauts including Merck & Co. and AstraZeneca Plc, so its growth prospects have attracted notable attention across the sector.
- Zacks•4 days ago
Mallinckrodt (MNK) to Separate Generics & Branded Businesses
Mallinckrodt (MNK) announces plans to split its generic and branded businesses into two different companies.
- Investor's Business Daily•6 days ago
These 16 Top-Rated Stocks Are Showing Strength In Volatile Market
Despite the volatile market, these 16 stocks to watch are showing relative strength and may pop if the stock market rebounds.
- Zacks•6 days ago
AbbVie Halts Rova-T Phase III Second-Line Lung Cancer Study
IDMC recommends AbbVie (ABBV) to stop enrolment in a late-stage study on its small cell lung cancer candidate, Rova-T.
- CNBC•6 days ago
Your first trade for Thursday, December 6
The " Fast Money " traders shared their first moves for the market open. Pete Najarian was a buyer of Merck MRK . Tim Seymour was a buyer of Boeing BA . Dan Nathan was a buyer of Disney DIS . Guy Adami was a buyer of Twitter TWTR .
- GlobeNewswire•6 days ago
BriaCell Presents Positive Efficacy Data with Lead Cancer Drug Candidate in Phase IIa Monotherapy and Excellent Initial Safety Data in Combination with KEYTRUDA® at a Major Breast Cancer Conference
Interim data indicate an excellent safety profile for the combination regimen in advanced breast cancer patients. Confirmed positive proof-of-concept with Bria-IMT™ Monotherapy demonstrates promising anti-tumor activity with excellent safety and tolerability in advanced breast cancer patients.
Markit•6 days agoSee what the IHS Markit Score report has to say about Merck & Co Inc.
Merck & Co Inc NYSE:MRK
- Zacks•7 days ago
Mylan Expands Recall of Valsartan to All Unexpired Lots
Mylan (MYL) expands recall of batches of blood pressure medicine in the United States to include all Valsartan-based products within expiry.
- Zacks•7 days ago
Are Options Traders Betting on a Big Move in Merck (MRK) Stock?
Investors need to pay close attention to Merck (MRK) stock based on the movements in the options market lately.
- ACCESSWIRE•7 days ago
Today's Research Reports on Trending Tickers: Pfizer and Merck & Co.
NEW YORK, NY / ACCESSWIRE / December 5, 2018 / U.S. equities plunged on Tuesday as skepticism over the U.S. and China’s ability to close a trade agreement weighed on the markets. The Dow Jones Industrial ...
- Bloomberg•7 days ago
Merck KGaA Partners With Startup for Image Tagging Software
“In health care alone, there are massive amounts of unstructured data generated every day in labs,” Michael Vande Vrede, head of digital products at Merck KGaA, said Tuesday at the conference on Neural Information Processing Systems (NeurIPS) in Montreal, where the two companies announced their collaboration. V7 has created software called Graphotate that makes it easier and faster to annotate scientific imagers and videos.
- Zacks•7 days ago
Incyte (INCY) Announces Positive Data on Jakafi for GVHD
Incyte (INCY) announces positive data on lead drug Jakafi at the ASH meet for the indication of acute GVHD.
- Motley Fool•8 days ago
3 Big Pharma Stocks Hitting 52-Week Highs -- Are They Buys?
Could big wins for these big pharma stocks in 2018 translate to more big returns?
- Zacks•8 days ago
Merck (MRK) Stock Sinks As Market Gains: What You Should Know
Merck (MRK) closed the most recent trading day at $79.22, moving -0.15% from the previous trading session.
